AOD-9604
Anti-Obesity Drug 9604 · hGH Fragment 176-191 · Tyr-hGH 177-191
A modified fragment of human growth hormone specifically targeting fat metabolism without the growth-promoting or diabetogenic effects of full GH.
Half-Life
~30-60 minutes
MW
1817.1 Da
Amino Acids
15 AA
Evidence
Moderate Evidence
Regulatory Status
Research compound. Passed Phase II clinical trials. Not currently FDA-approved.
Research reference values only. Confirm all parameters with current literature and your clinician.
Looking for multi-compound protocols?
Browse educational protocol discussions that include AOD-9604.
Related Compounds
Tesamorelin
FDA-approved GHRH analogue specifically studied for visceral fat reduction in HIV-associated lipodystrophy, with broader anti-aging research interest.
CJC-1295
A long-acting GHRH analogue with a Drug Affinity Complex that extends its half-life dramatically, allowing weekly dosing for sustained GH elevation.
Ipamorelin
A highly selective GH secretagogue and ghrelin receptor agonist known for clean GH release without significant cortisol or prolactin stimulation.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.